long intergenic non-protein coding RNA 434Genealiases: []
Q-omics provides the consensus-scored LINC00434 profile across patient tissues and cancer cell-line models. LINC00434 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC00434 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, LINC00434 RNA expression shows 5,920 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, KIRC, and STAD as cancer lineages where LINC00434 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00434 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00434 survival associations across molecular data types. LINC00434 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00434 RNA expression–survival associations across cancer types. High LINC00434 expression shows unfavorable associations in HNSC, LUSC, STAD, READ and KICH, but favorable associations in LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC00434 RNA expression.
This table summarizes LINC00434 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00434. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00434 shows lower tumor expression in KIRC, LUSC, KICH and COAD and higher tumor expression in UCEC and BRCA. The KIRC box plot shows higher LINC00434 RNA expression in normal versus tumor tissue (log2 FC = −0.077, t-test p < 0.001).
This table shows molecular features associated with LINC00434 in patient tissues and cancer cell lines. In patient samples, LINC00434 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
